Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Impact of site of metastases in pancreatic ductal adenocarcinoma.
Authors
Adeel Arshad
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Adeel Arshad , Songzhu Zhao , Lai Wei , Julie Stephens , Ashish Manne , Anne M. Noonan , Shafia Rahman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 708)
DOI
10.1200/JCO.2024.42.3_suppl.708
Abstract #
708
Poster Bd #
N17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.
First Author: Kelsey Klute
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
First Author: Syvart Dennen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.
First Author: Andrea Pretta
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Does metformin use effect overall survival for patients with pancreatic cancer?
First Author: Ravi Ramjeesingh